Want to see TSE:VPT full AI Analyst Report?
VPT Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume79.10K
Average Volume (3M)104.32K
Market Cap
C$17.36M
Enterprise ValueC$22.72
Total Cash (Recent Filing)C$55.39K
Total Debt (Recent Filing)C$2.60M
Price to Earnings (P/E)―
Beta-0.70
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding192,877,940
10 Day Avg. Volume122,816
30 Day Avg. Volume104,322
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue AccelerationThe sharp increase in revenue indicates meaningful commercial expansion and growing customer or product adoption. If this momentum persists, a larger revenue base could improve operating leverage, support broader market penetration, and create a foundation for stronger future earnings despite current losses.
Reported Gross-margin StrengthA gross margin near two-thirds of revenue indicates the company retains a substantial portion of sales after direct costs. This provides potential room to fund operating expenses and eventual growth investments, although durable benefit depends on scaling revenue and controlling overhead.
Lower Operating Cash BurnThe reduction in operating cash outflow suggests some improvement in cash discipline or business economics compared with the prior year. While cash generation remains negative, a sustained improvement could reduce funding needs and give management more time to convert revenue growth into profitability.
Bears Say
Deeply Negative Equity And Rising DebtNegative equity and materially higher debt signal a severely weakened capital structure, reducing financial flexibility and asset backing. This can make future financing more difficult or dilutive, while elevated obligations increase the company’s exposure if operating performance does not improve.
Persistent Cash Funding RequirementContinued cash outflows mean the company is not yet self-funding its operations, even with substantial revenue growth. Ongoing funding needs can constrain investment choices and may require additional capital, creating dilution or refinancing pressure over the medium term.
Severe UnprofitabilityLosses remain exceptionally large relative to the company’s revenue base, showing that growth has not yet translated into operating leverage. Without a clear improvement in cost absorption, the business may continue consuming capital and face difficulty converting commercial momentum into durable shareholder value.
VPT FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is C$17.36M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Dec 02, 2026 which is in 76 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
VentriPoint Diagnostics Ltd released its earnings results on Sep 01, 2026. The company reported -C$0.007 earnings per share for the quarter.
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,877,940 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
VentriPoint Diagnostics Ltd reported an EPS of -C$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.